Arrowhead Pharma (NASDAQ:ARWR) 주식

Arrowhead Pharma

Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.

Mid Cap

News

Movers

Trading Ideas

ACHR

ARWR

BHVN

Hims & Hers Health, Inc. Class A Common Stock

HIMS

IREN

JOBY

SOUN

SRPT

SRRK

URBN

이 8개 중형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 아처 에비에이션(NYSE:ACHR) 주식은 지난주 65.57% 급등했다.

아처 및 어번 아웃피터스는 지난주 최고 성과를 보여준 8개 중형주 중 일부 (11월 25일-29일)

Large Cap

CPRT

ESTC

EXAS

MRNA

RIVN

RKLB

SNAP

ULTA

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 리비안 오토모티브(NASDAQ:RIVN)의 주식이 22.06% 급등했다. 이는 회사가 66억 달러의 에너지부(DOE)의 대출 약정을 확보한 후 발생한 일이다.

리비안, 로켓랩 및 모더나가 지난주 최고 성과를 보여준 10개 대형주 중 일부 (11월 25일-29일)

Biotech

Earnings

Equities

Markets

AMGN

RPRX

목요일 시장 마감 후 암젠(NASDAQ:AMGN)은 1분기 재무 결과를 발표했다. 여기에는 몇 가지 핵심 내용을 보자. 세부 사항 (The Details): 암젠은 분기별 이익을 주당 3.96달러로 보고했는데, 이는 분석가 컨센서스인 3.87달러보다 2.33% 높았다. 이 회사는 호라이즌(Horizon) 인수로 인한 운영 및 이자 비용 증가로 인해 주당순이익(EPS)이 1% 감소했으며 매출 증가로 부분적으로 상쇄되었다고 밝혔다.

암젠: 예상보다 좋은 1분기 실적 및 5,000만 달러의 마일스톤 지급금 수입에 주가 급등

Arrowhead Pharmaceuticals, Inc. - Common Stock

Arrowhead Pharmaceuticals Inc

B. Riley Securities analyst Mayank Mamtani reiterates Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) with a Buy and lowers the price target from $51 to $38.

Price Target

Reiteration

Analyst Ratings

B. Riley Securities Reiterates Buy on Arrowhead Pharma, Lowers Price Target to $38

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>RXRX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$8.00</td>
<td>$26.6K</td>
<td>2.5K</td>
<td>4.6K</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$20.00</td>
<td>$95.5K</td>
<td>1.8K</td>
<td>2.0K</td>
</tr>
<tr>
<td>WST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$200.00</td>
<td>$192.0K</td>
<td>55</td>
<td>286</td>
</tr>
<tr>
<td>EXAS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$45.00</td>
<td>$153.7K</td>
<td>609</td>
<td>250</td>
</tr>
<tr>
<td>MRK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$85.00</td>
<td>$26.1K</td>
<td>2.6K</td>
<td>216</td>
</tr>
<tr>
<td>SWTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$50.00</td>
<td>$56.0K</td>
<td>1.3K</td>
<td>201</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$60.00</td>
<td>$40.1K</td>
<td>13.3K</td>
<td>156</td>
</tr>
<tr>
<td>ARWR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$20.00</td>
<td>$27.4K</td>
<td>385</td>
<td>110</td>
</tr>
<tr>
<td>WGS</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$77.50</td>
<td>$35.0K</td>
<td>176</td>
<td>46</td>
</tr>
<tr>
<td>SRPT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$100.00</td>
<td>$35.6K</td>
<td>602</td>
<td>30</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For RXRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>), we notice a put option sweep that happens to be bullish, expiring in 35 day(s) on March 21, 2025. This event was a transfer of 533 contract(s) at a $8.00 strike. This particular put needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $26.6K, with a price of $50.0 per contract. There were 2587 open contracts at this strike prior to today, and today 4649 contract(s) were bought and sold. 
• For MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we notice a put option trade that happens to be bullish, expiring in 336 day(s) on January 16, 2026. This event was a transfer of 500 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $95.5K, with a price of $191.0 per contract. There were 1849 open contracts at this strike prior to today, and today 2000 contract(s) were bought and sold. 
• For WST (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>), we notice a call option sweep that happens to be bearish, expiring in 308 day(s) on December 19, 2025. This event was a transfer of 40 contract(s) at a $200.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $192.0K, with a price of $4800.0 per contract. There were 55 open contracts at this strike prior to today, and today 286 contract(s) were bought and sold. 
• Regarding EXAS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>), we observe a put option trade with bullish sentiment. It expires in 336 day(s) on January 16, 2026. Parties traded 250 contract(s) at a $45.00 strike. The total cost received by the writing party (or parties) was $153.7K, with a price of $615.0 per contract. There were 609 open contracts at this strike prior to today, and today 250 contract(s) were bought and sold. 
• For MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we notice a put option trade that happens to be bullish, expiring in 154 day(s) on July 18, 2025. This event was a transfer of 39 contract(s) at a $85.00 strike. The total cost received by the writing party (or parties) was $26.1K, with a price of $670.0 per contract. There were 2690 open contracts at this strike prior to today, and today 216 contract(s) were bought and sold. 
• For SWTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>), we notice a call option trade that happens to be bearish, expiring in 7 day(s) on February 21, 2025. This event was a transfer of 50 contract(s) at a $50.00 strike. The total cost received by the writing party (or parties) was $56.0K, with a price of $1120.0 per contract. There were 1300 open contracts at this strike prior to today, and today 201 contract(s) were bought and sold. 
• Regarding CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we observe a call option sweep with bearish sentiment. It expires in 35 day(s) on March 21, 2025. Parties traded 59 contract(s) at a $60.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $40.1K, with a price of $680.0 per contract. There were 13329 open contracts at this strike prior to today, and today 156 contract(s) were bought and sold. 
• For ARWR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>), we notice a call option sweep that happens to be bullish, expiring in 126 day(s) on June 20, 2025. This event was a transfer of 100 contract(s) at a $20.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $27.4K, with a price of $276.0 per contract. There were 385 open contracts at this strike prior to today, and today 110 contract(s) were bought and sold. 
• Regarding WGS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>), we observe a call option trade with neutral sentiment. It expires in 7 day(s) on February 21, 2025. Parties traded 35 contract(s) at a $77.50 strike. The total cost received by the writing party (or parties) was $35.0K, with a price of $1000.0 per contract. There were 176 open contracts at this strike prior to today, and today 46 contract(s) were bought and sold. 
• For SRPT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), we notice a put option sweep that happens to be bullish, expiring in 336 day(s) on January 16, 2026. This event was a transfer of 30 contract(s) at a $100.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $35.6K, with a price of $1177.0 per contract. There were 602 open contracts at this strike prior to today, and today 30 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

RXRX

SWTX

10 Health Care Stocks With Whale Alerts In Today's Session

WIIM

Arrowhead Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q1 financial results.

RBC Capital analyst Luca Issi reiterates Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) with a Outperform and maintains $42 price target.

RBC Capital Reiterates Outperform on Arrowhead Pharma, Maintains $42 Price Target

Chardan Capital analyst Keay Nakae maintains Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) with a Buy and maintains $60 price target.

Chardan Capital Maintains Buy on Arrowhead Pharma, Maintains $60 Price Target

Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) reported quarterly losses of $(1.39) per share which missed the analyst consensus estimate of $(0.63) by 120.63 percent. This is a 12.1 percent decrease over losses of $(1.24) per share from the same period last year. The company reported quarterly sales of $2.50 million which missed the analyst consensus estimate of $65.47 million by 96.18 percent. This is a 29.60 percent decrease over sales of $3.55 million the same period last year.

Earnings Misses

Arrowhead Pharma Q1 2025 GAAP EPS $(1.39) Misses $(0.63) Estimate, Sales $2.50M Miss $65.47M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Hain Celestial Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAIN#NASDAQ">HAIN</a>) is likely to report quarterly earnings at $0.12 per share on revenue of $431.01 million. 
• Monday.Com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) is expected to report quarterly earnings at $0.79 per share on revenue of $261.34 million. 
• Tower Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSEM#NASDAQ">TSEM</a>) is expected to report quarterly earnings at $0.53 per share on revenue of $387.09 million. 
• Edgewell Personal Care (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPC#NYSE">EPC</a>) is projected to report quarterly earnings at $0.12 per share on revenue of $480.16 million. 
• McDonald's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) is estimated to report quarterly earnings at $2.86 per share on revenue of $6.48 billion. 
• Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) is projected to report quarterly earnings at $1.55 per share on revenue of $1.15 billion. 
• CSP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSPI#NASDAQ">CSPI</a>) is estimated to report earnings for its first quarter. 
• Ispire Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPR#NASDAQ">ISPR</a>) is likely to report quarterly loss at $0.03 per share on revenue of $59.50 million. 
• Motorcar Parts of America (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPAA#NASDAQ">MPAA</a>) is projected to report quarterly earnings at $0.43 per share on revenue of $179.50 million. 
• Roivant Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROIV#NASDAQ">ROIV</a>) is likely to report quarterly loss at $0.22 per share on revenue of $5.00 million. 
• Insperity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSP#NYSE">NSP</a>) is estimated to report quarterly earnings at $0.02 per share on revenue of $1.60 billion. 
• GCM Grosvenor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCMG#NASDAQ">GCMG</a>) is projected to report quarterly earnings at $0.23 per share on revenue of $158.60 million. 
• Rockwell Automation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>) is likely to report quarterly earnings at $1.67 per share on revenue of $1.88 billion. 
• PowerFleet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIOT#NASDAQ">AIOT</a>) is estimated to report quarterly earnings at $0.05 per share on revenue of $99.43 million. 
• ON Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) is expected to report quarterly earnings at $0.98 per share on revenue of $1.76 billion. 
• Alexander's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALX#NYSE">ALX</a>) is estimated to report quarterly earnings at $3.71 per share on revenue of $55.20 million. 
• Loews (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/L#NYSE">L</a>) is expected to report earnings for its fourth quarter. 
• CNA Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNA#NYSE">CNA</a>) is expected to report quarterly earnings at $1.21 per share on revenue of $3.62 billion. 
• ORIX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IX#NYSE">IX</a>) is estimated to report earnings for its third quarter. 
<h3>Companies Reporting After The Bell</h3>
• Arch Capital Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACGL#NASDAQ">ACGL</a>) is expected to report quarterly earnings at $1.80 per share on revenue of $3.95 billion. 
• RCI Hospitality Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RICK#NASDAQ">RICK</a>) is projected to report quarterly earnings at $0.00 per share on revenue of $81.82 million. 
• Ark Restaurants (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARKR#NASDAQ">ARKR</a>) is expected to report earnings for its first quarter. 
• Compass Minerals Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMP#NYSE">CMP</a>) is projected to report earnings for its first quarter. 
• Radiant Logistics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/RLGT#AMEX">RLGT</a>) is projected to report quarterly earnings at $0.10 per share on revenue of $220.60 million. 
• Cresud SACIF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRESY#NASDAQ">CRESY</a>) is likely to report earnings for its second quarter. 
• Prospect Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSEC#NASDAQ">PSEC</a>) is expected to report quarterly earnings at $0.14 per share on revenue of $189.67 million. 
• SelectQuote (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLQT#NYSE">SLQT</a>) is projected to report quarterly earnings at $0.00 per share on revenue of $447.00 million. 
• SPDR ICE Preferred Securities ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSK#NYSE">PSK</a>) is projected to report quarterly earnings at $0.22 per share on revenue of $121.00 million. 
• PetMed Express (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PETS#NASDAQ">PETS</a>) is estimated to report quarterly loss at $0.01 per share on revenue of $60.00 million. 
• Quipt Home Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QIPT#NASDAQ">QIPT</a>) is likely to report earnings for its first quarter. 
• RGC Resources (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGCO#NASDAQ">RGCO</a>) is projected to report quarterly earnings at $0.50 per share on revenue of $26.00 million. 
• Fluence Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) is projected to report quarterly loss at $0.21 per share on revenue of $375.22 million. 
• Columbus McKinnon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCO#NASDAQ">CMCO</a>) is expected to report quarterly earnings at $0.74 per share on revenue of $252.56 million. 
• Origin Agritech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEED#NASDAQ">SEED</a>) is estimated to report earnings for its Fiscal Year 2024. 
• Lattice Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) is likely to report quarterly earnings at $0.19 per share on revenue of $117.09 million. 
• Unitil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UTL#NYSE">UTL</a>) is estimated to report quarterly earnings at $0.95 per share on revenue of $145.00 million. 
• Beyond Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) is estimated to report quarterly loss at $0.15 per share on revenue of $934 thousand. 
• SPS Commerce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPSC#NASDAQ">SPSC</a>) is expected to report quarterly earnings at $0.87 per share on revenue of $169.29 million. 
• Bank of N.T Butterfield (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTB#NYSE">NTB</a>) is projected to report quarterly earnings at $1.14 per share on revenue of $143.43 million. 
• Simpson Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSD#NYSE">SSD</a>) is projected to report quarterly earnings at $1.29 per share on revenue of $498.53 million. 
• Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) is estimated to report quarterly earnings at $4.10 per share on revenue of $2.78 billion. 
• TIM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TIMB#NYSE">TIMB</a>) is estimated to report earnings for its fourth quarter. 
• Vornado Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNO#NYSE">VNO</a>) is estimated to report quarterly earnings at $0.51 per share on revenue of $447.75 million. 
• Axcelis Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACLS#NASDAQ">ACLS</a>) is expected to report quarterly earnings at $1.25 per share on revenue of $244.95 million. 
• Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) is likely to report quarterly loss at $1.10 per share on revenue of $14.09 million. 
• Kilroy Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRC#NYSE">KRC</a>) is likely to report quarterly earnings at $1.03 per share on revenue of $280.21 million. 
• Apollo Comml Real Est (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARI#NYSE">ARI</a>) is likely to report quarterly earnings at $0.22 per share on revenue of $48.20 million. 
• Mitek Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MITK#NASDAQ">MITK</a>) is expected to report quarterly earnings at $0.13 per share on revenue of $36.05 million. 
• Harmonic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLIT#NASDAQ">HLIT</a>) is likely to report quarterly earnings at $0.37 per share on revenue of $212.45 million. 
• Amkor Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>) is estimated to report quarterly earnings at $0.38 per share on revenue of $1.66 billion. 
• Danaos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAC#NYSE">DAC</a>) is estimated to report quarterly earnings at $6.95 per share on revenue of $261.56 million. 
• Coty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COTY#NYSE">COTY</a>) is projected to report quarterly earnings at $0.21 per share on revenue of $1.73 billion. 
• Watts Water Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTS#NYSE">WTS</a>) is estimated to report quarterly earnings at $1.92 per share on revenue of $537.61 million. 
• CoreCivic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXW#NYSE">CXW</a>) is estimated to report quarterly earnings at $0.30 per share on revenue of $465.17 million. 
• NGL Energy Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGL#NYSE">NGL</a>) is estimated to report quarterly earnings at $0.13 per share on revenue of $1.72 billion. 
• Medpace Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) is projected to report quarterly earnings at $3.12 per share on revenue of $535.01 million. 
• Astera Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) is projected to report quarterly earnings at $0.26 per share on revenue of $127.91 million. 
• Inspire Medical Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSP#NYSE">INSP</a>) is estimated to report quarterly earnings at $0.72 per share on revenue of $232.90 million. 
• Pennant Park Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNNT#NYSE">PNNT</a>) is expected to report quarterly earnings at $0.21 per share on revenue of $35.59 million. 
• PennantPark Floating Rate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFLT#NYSE">PFLT</a>) is projected to report quarterly earnings at $0.32 per share on revenue of $59.48 million. 
• Cincinnati Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CINF#NASDAQ">CINF</a>) is expected to report quarterly earnings at $1.87 per share on revenue of $2.63 billion. 
• Brixmor Property Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRX#NYSE">BRX</a>) is projected to report earnings for its fourth quarter. 
• Credicorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAP#NYSE">BAP</a>) is likely to report quarterly earnings at $4.66 per share on revenue of $1.48 billion. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACGL

ACLS

AIOT

ALAB

AMKR

ARKR

CINF

CMCO

COTY

CRESY

CSPI

FLNC

GCMG

HAIN

HLIT

INCY

INSP

ISPR

LSCC

MEDP

MITK

MNDY

MPAA

PETS

PFLT

PNNT

PSEC

QIPT

RGCO

RICK

RLGT

ROIV

SEED

SLQT

SPSC

TIMB

TSEM

VRTX

XAIR

Earnings Scheduled For February 10, 2025

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) with a Buy and maintains $80 price target.

HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $80 Price Target

S&amp;P 500 constituent Apollo Global Management is acquiring Barnes Group in a deal expected to be completed soon pending final conditions.&nbsp;

Arrowhead Pharmaceuticals To Replace  Barnes Group In S&P SmallCap 600, Effective Prior To Opening Of Trading On January 27

GWRE

Guidewire Software To Replace Arrowhead Pharmaceuticals In S&P MidCap 400, Effective Prior To Opening Of Trading On January 27

Arrowhead Pharmaceuticals Announces FDA Acceptance of New Drug Application For Plozasiran In Treatment Of Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals Announced Interim Results From A Phase 1/2A Clinical Study Of ARO-CFB, The Company's Investigational RNA Interference (RNAi) Therapeutic Targeting Complement Factor B Being Developed As A Potential Treatment For Complement Mediated Diseases

HC Wainwright &amp; Co. analyst Patrick Trucchio maintains Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) with a Buy and raises the price target from $60 to $80.

HC Wainwright & Co. Maintains Buy on Arrowhead Pharma, Raises Price Target to $80

<ul>
<li>In preclinical studies, investigational ARO-ALK7 silenced Activin receptor-like kinase 7 (ALK7) expression in adipose tissue, which led to reduced body weight and fat mass with preservation of lean muscle</li>
</ul>

Health Care

General

Arrowhead Pharmaceuticals Has Filed A Request For Regulatory Clearance To Initiate A Phase 1/2a Trial Of ARO-ALK7 As A Potential Treatment For Obesity

These eight mid-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Archer Aviation Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) shares skyrocketed 65.57% last week.</li>
<li>Scholar Rock Holding Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRRK#NASDAQ">SRRK</a>) stock jumped 49.61%  after rival Biohaven Ltd.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>) taldefgrobep for spinal muscular <a href="https://www.benzinga.com//node/42169246" target="_blank" rel="noreferrer noopener">atrophy failed its Phase 3 study</a>.</li>
<li>Arrowhead Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) shares escalated 42.40% after it entered into a global licensing and collaboration agreement with Sarepta Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) for multiple clinical <a href="https://www.benzinga.com//node/42196870" target="_blank" rel="noreferrer noopener">and preclinical siRNA programs</a>.</li>
<li>Iris Energy Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) stock surged 38.99% after the company reported first-quarter results and several analysts raised <a href="https://www.benzinga.com//node/42214256" target="_blank" rel="noreferrer noopener">the price forecast on the stock</a>.</li>
<li>Hims &amp; Hers Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares upped 33.42% in response to President-elect Donald Trump's plans to nominate Marty Makary to lead the <a href="https://www.benzinga.com//node/42177219" target="_blank" rel="noreferrer noopener">Food and Drug Administration (FDA)</a>.</li>
<li>SoundHound AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) stock grew 33.38%. The company recently announced the deployment of its conversational AI agent, Amelia, at <a href="https://www.benzinga.com//node/42145826" target="_blank" rel="noreferrer noopener">Apivia Courtage as part of the AEMA Group</a>.</li>
<li>Joby Aviation, Inc.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) stock upped 31.62% after Toyota Motor Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TM#NYSE">TM</a>) <a href="https://www.benzinga.com//node/42169194" target="_blank" rel="noreferrer noopener">invested half a billion dollars</a> in it.</li>
<li>Urban Outfitters, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) shares increased 30.43% after the company reported third-quarter earnings and several analysts raised <a href="https://www.benzinga.com//node/42221225" target="_blank" rel="noreferrer noopener">the price forecast on the stock</a>.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/12/42256613/rivian-automotive-rocket-lab-and-moderna-are-among-top-10-large-cap-gainers-last-week-nov-25-nov-29-are-the-others-in-your-portfolio" target="_blank" rel="noreferrer noopener">Rivian Automotive, Rocket Lab And Moderna Are Among Top 10 Large-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio?</a></li>
<li><a href="https://www.benzinga.com/news/large-cap/24/12/42256757/reddit-grab-and-autodesk-are-among-top-11-large-cap-losers-last-week-nov-25-nov-29-are-the-others-in-your-portfolio" target="_blank" rel="noreferrer noopener">Reddit, Grab And Autodesk Are Among Top 11 Large-Cap Losers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio?</a></li>
</ul>
Image via Archer

Archer Aviation, Hims & Hers Health And Urban Outfitters Are Among Top 8 Mid-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio?

These ten large-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) shares jumped 22.06% after securing a<a href="https://www.benzinga.com//node/42184005" target="_blank" rel="noreferrer noopener"> $6.6 billion DOE loan commitment</a>.</li>
<li>Rocket Lab USA, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) stock surged 21.73% after it secured a $23.9 million CHIPS Act grant to enhance its <a href="https://www.benzinga.com//node/42216210" target="_blank" rel="noreferrer noopener">semiconductor operations in New Mexico</a>.</li>
<li>Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) stock upped 20.67% after the company announced a global licensing and collaboration agreement with Arrowhead Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) for <a href="https://www.benzinga.com//node/42196870" target="_blank" rel="noreferrer noopener">multiple clinical and preclinical siRNA programs</a>.</li>
<li>Exact Sciences Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) stock increased 16.98%. The Centers for Medicare &amp; Medicaid Services posted final payment determinations for its <a href="https://www.benzinga.com//node/42195803" target="_blank" rel="noreferrer noopener">2025 Clinical Laboratory Fee Schedule</a>.</li>
<li>Elastic N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) shares rose 16.29%. Wedbush Securities analyst Daniel Ives has significantly increased his optimism on the next phase of the AI revolution, focusing on its <a href="https://www.benzinga.com//node/42171519" target="_blank" rel="noreferrer noopener">transformative impact on the software sector</a>.</li>
<li>Ulta Beauty, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) shares upped 14.13%. Citigroup analysts raised the<a href="https://www.benzinga.com/quote/ulta/analyst-ratings" target="_blank" rel="noreferrer noopener"> price forecast on the stock</a>.</li>
<li>Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) <a href="https://www.benzinga.com//node/42197195" target="_blank" rel="noreferrer noopener">shares surged 12.58%</a> last week.</li>
<li>Ralph Lauren Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>) stock gained 11.72% last week.</li>
<li>Copart, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRT#NASDAQ">CPRT</a>) stock was up 11.41% after the company reported better-than-expected Q1 sales results.</li>
<li>Snap Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) stock increased 12.18%. Citigroup analysts raised the <a href="https://www.benzinga.com/quote/snap/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast on the stock</a>.</li>
</ol>
Photo by rblfmr via Shutterstock

Rivian Automotive, Rocket Lab And Moderna Are Among Top 10 Large-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio?

Bernstein analyst William Pickering maintains Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) with a Market Perform and lowers the price target from $27 to $24.

Bernstein Maintains Market Perform on Arrowhead Pharma, Lowers Price Target to $24

U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Wednesday.
Shares of Iris Energy Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) rose sharply during Wednesday's session on the heels of the company's first-quarter financial results. Multiple analysts raised price <a href="https://www.benzinga.com/quote/IREN/earnings">targets following the print</a>.
After the market close on Tuesday, Iris reported first-quarter Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) mining revenue of $49.6 million. The company reported a 28% increase in AI Cloud Services revenue quarter-over-quarter to $3.2 million.
Iris Energy shares jumped 30.8% to $12.51 on Wednesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Agora, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/API#NASDAQ">API</a>) gained 26.1% to $5.98.</li>
<li>Arrowhead Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) shares gained 20.9% to $25.45 following FY 2024 results.</li>
<li>Murano Global Investments Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNO#NASDAQ">MRNO</a>) jumped 18.4% to $11.13.</li>
<li>Kingsoft Cloud Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) gained 17.1% to $6.99.</li>
<li>Urban Outfitters, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) shares surged 16% to $46.58 following third-quarter earnings. Citigroup upgraded the stock to Buy following the report.</li>
<li>Bit Digital, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTBT#NASDAQ">BTBT</a>) gained 14.4% to $4.2802.</li>
<li>Fate Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FATE#NASDAQ">FATE</a>) gained 14.4% to $3.0650.</li>
<li>Hut 8 Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) shares jumped 12.8% to $27.56.</li>
<li>Archer Aviation Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) gained 12.2% to $8.10.</li>
<li>MINISO Group Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNSO#NASDAQ">MNSO</a>) climbed 7.2% to $18.66.</li>
<li>Bloom Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) shares gained 5.8% to $27.69.</li>
<li>Ambarella, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMBA#NASDAQ">AMBA</a>) gained 5% to $71.82 after the company on Tuesday reported a year-over-year increase in third-quarter revenue results..</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42213467/urban-outfitters-to-rally-around-47-here-are-10-top-analyst-forecasts-for-wednesday">Urban Outfitters To Rally Around 47%? Here Are 10 Top Analyst Forecasts For Wednesday</a></li>
</ul>

$BTC

AMBA

BTBT

FATE

MNSO

MRNO

Iris Energy, Arrowhead Pharmaceuticals, Urban Outfitters And Other Big Stocks Moving Higher On Wednesday

Press Releases

Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity

Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity

Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results

Guidewire Software Set to Join S&P MidCap 400; Arrowhead Pharmaceuticals to Join S&P SmallCap 600

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics

Comments

Arrowhead Pharma

뉴스

파트너 / 기고자

벤징가 글로벌